| ［1］ Gaspar LE, McNamara EJ, Gay EG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years［J］. Clin Lung Cancer, 2012, 13(2): 115-122. DOI: 10.1016/j.cllc.2011.05.008.
［2］ Schabath MB, Nguyen A, Wilson P, et al. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients［J］. Lung Cancer, 2014, 86(1): 14-21. DOI: 10.1016/j.lungcan.2014.07.014.
［3］ Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, openlabel, phase 3 trial［J］. Lancet Oncol, 2017, 18(5): 663-671. DOI: 10.1016/S1470-2045(17)30230-9.
［4］ Cheng Y, Wang Q, Li K, et al. Anlotinib as thirdline or furtherline treatment in relapsed SCLC: a multicentre, randomized, doubleblind phase 2 trial［J］. J Thorac Oncol, 2018, 13 (10 Supple): S351-S352. DOI: https://doi.org/10.1016/j.jtho.2018.08.308.
［5］ Beedie SL, Mahony C, Walker HM, et al. Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model［J］. Sci Rep, 2016, 6: 30038. DOI: 10.1038/srep30038.
［6］ Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors［J］. J Hematol Oncol, 2016, 9(1): 105. DOI: 10.1186/s13045-016-0332-8. |
